



OPEN ACCESS

EDITED BY
Chen Ling,
Fudan University, China

REVIEWED BY
Yajun Lin,
Beijing Hospital, Peking University,
China
Yunping Song,
Tongji University, China
Situo Zhou,
Central South University, China

*CORRESPONDENCE
Ke-Wei Sun,
keweisun550@163.com

[†]The authors have contributed equally
to this work

SPECIALTY SECTION
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology

RECEIVED 26 July 2022
ACCEPTED 28 September 2022
PUBLISHED 20 October 2022

CITATION
Tang D, Wang R-Y, Sun K-W, Wu Y,
Ding L and Mo Y (2022), Network
pharmacology-based prediction of
active compounds in the Wenyang
Jiedu Huayu formula acting on acute-
on-chronic liver failure with
experimental support *in vitro* and *in vivo*.
Front. Pharmacol. 13:1003479.
doi: 10.3389/fphar.2022.1003479

COPYRIGHT
© 2022 Tang, Wang, Sun, Wu, Ding and
Mo. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Network pharmacology-based prediction of active compounds in the Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental support *in vitro* and *in vivo*

Dan Tang^{1†}, Ruo-Yu Wang^{1†}, Ke-Wei Sun^{1*}, Yunan Wu¹,
Lin Ding¹ and Yang Mo²

¹Department of Hepatology, The First Hospital of Hunan University of Traditional Chinese Medicine, Changsha, China, ²Academic Affairs Office, Hunan University of Traditional Chinese Medicine, Changsha, China

Acute-on-chronic liver failure (ACLF) is characterized by undermined liver function, massive necrosis/apoptosis of hepatocytes, and hepatic inflammatory cell recruitment, leading to multiorgan failure. Traditional Chinese medicine (TCM) has been widely applied in clinical and experimental studies of ACLF. In this study, 23 compounds with 6,386 drug targets were obtained from Wenyang Jiedu Huayu (WYJDHY), and 8,096 genes were identified as ACLF disease targets, among which 3,132 were overlapping co-targets. Expression profile analysis identified 105 DEGs among the co-targets, which were associated with biological activities such as lymphocyte activation, immune response regulation, and pathways such as Th17 cell differentiation and NF- κ B signaling. After PPI analysis and network construction, atractylenolide I (AT-1) has been identified as the hub active ingredient of the WYJDHY formula. LPS stimulation inhibited rat hepatocytes' BRL 3A cell viability, promoted cell apoptosis, increased the levels of ALT, AST, IL-6, and VCAM-1 within the culture medium, and activated NF- κ B signaling, whereas AT-1 treatment significantly attenuated LPS-induced toxicity on BRL 3A cells. Furthermore, the NF- κ B signaling inhibitor PDTC exerted effects on LPS-stimulated BRL 3A cells similar to those of AT-1, and the combination of PDTC and AT-1 further attenuated LPS-induced toxicity on BRL 3A cells. *In vivo*, AT-1 alone or with PDTC improved the symptoms and local inflammation in ACLF model rats. In conclusion, 23 active ingredients of six herbs in the WYJDHY formula were retrieved, and 105 co-targets were differentially expressed in ACLF. AT-1 exerts protective effects on LPS-stimulated hepatocytes and ACLF rats, possibly by inhibiting the NF- κ B pathway.

KEYWORDS

acute-on-chronic liver failure, Wenyang Jiedu Huayu formula, network pharmacology, atractylenolide I, rat hepatocytes, ACLF rat model

Introduction

Acute-on-chronic liver failure (ACLF) is characterized by undermined liver function and massive necrosis/apoptosis of hepatocytes and hepatic inflammatory cell recruitment, resulting in multiorgan failure (Arroyo et al., 2015). Chronic liver disease, severe decompensation, and liver failure occurring in a short amount of time might result in ACLF (Liver et al., 2019). Hepatitis B virus (HBV)-induced liver failure is the most frequent form of liver diseases, with ACLF being the most common clinical manifestation, accounting for 80–90% of cases in China (Liver et al., 2019), with a high mortality rate, numerous complications, and extremely limited treatment (Liver et al., 2013; Kabbani et al., 2021). Despite significant interventions, the short-term rates of liver failure mortality remain unacceptable, owing mostly to insufficient response to standard therapy and a dearth of liver transplantation options (Bernal et al., 2015). Moreover, some of the illness management practices following conventional Western medicine treatment are inadequate, leaving clinical needs unmet (Gao et al., 2017).

Numerous factors, such as endotoxin and pro-inflammatory cytokines, have been linked to the disease's pathogenesis (Zhou M. et al., 2019; Kessoku et al., 2021; Lad et al., 2021). Host immunity, resulting in the release of pro-inflammatory cytokines and activation of the excessive immune cascade, is accompanied by significant liver damage in the early stages of ACLF (Liu, 2009). Pro-inflammatory cytokines, such as tumor necrosis factor (TNF), gradually increase in correlation with ACLF's severity and prognosis (Zou et al., 2009; Wang Z. L. et al., 2016). Toll-like receptor (TLR) pathways might also influence the activation of multiple immediate early genes associated with the pro-inflammatory cytokines in the process of liver failure (Sun et al., 2009; McCabe et al., 2012). Moreover, as a critical factor of the TLR pathway, NF- κ B signaling exerts crucial effects on TNF cascades (Napetschnig and Wu, 2013). The Akt pathway is tightly associated with immune modulation after TLR activation (Zhang and Lu, 2015). Several reagents have been reported to alleviate ACLF by regulating the NF- κ B pathway, including trichostatin A (Zhang et al., 2015), ginsenoside Rg1 (Zhao et al., 2021), and plumbagin (Wang H. et al., 2016). Furthermore, the NF- κ B pathway has been implicated in the progression of ACLF. Zhang et al. (2022b) demonstrated that NF- κ B activation and increased inflammation participated in the pathogenesis of HBV-ACLF injury. Yang et al. (2014) reported that the inhibition of NF- κ B and TNF- α resulted in different effects on ACLF rats. Therefore, identifying more efficient reagents modulating the NF- κ B pathway might provide promising candidates for ACLF treatment.

In recent years, TCM has been widely used in clinical and experimental studies of ACLF; it has been confirmed to have some advantages in protecting liver function and delaying disease progression (Chen et al., 2019). The Wenyang Jiedu Huayu (WYJDHY) formula, which is composed of FuZi (*Aconiti Lateralis Radix Praeparata*), BaiZhu (*Atractylodis Macrocephalae Rhizoma*), Chishao (*Radix Paeoniae Rubra*), YinChen (*Artemisiae Scopariae Herba*), DanShen (*Salvia miltiorrhiza* Bunge), and YiYiRen (*Coix lacryma-jobi* L.), has long been used for jaundice and liver failure treatment in TCM. The WYJDHY formula could improve liver

failure patients' liver function and blood coagulation function (Zuo, 2021). In this formula, Chishao is bitter and slightly cold in nature, which is used to clear heat and cool the blood to resolve blood stasis, whereas FuZi warms the spleen and kidneys to prevent the bitter cold from injuring the stomach, and these two are the monarch drugs in the formula. The combination of YinChen and DanShen is the subject herb to strengthen the effect of clearing heat and dampness and activating blood circulation to remove blood stasis. Then, BaiZhu and YiYiRen are used to strengthen the spleen and dry dampness to prevent the drugs from damaging the spleen and stomach. The whole formula is based on the treatment method of "clearing heat and dampness, cooling blood, detoxifying, and activating blood stasis" for jaundice in liver failure, emphasizing warming Yang and strengthening the spleen. The experimental studies confirmed (Chen et al., 2013; Wang et al., 2013) that WYJDHY, detoxifying and resolving blood stasis, can increase intestinal sIgA secretion, lower serum endotoxin levels, and reduce hepatic NF- κ B expression. Our previous study has also confirmed that the warming Yang method using BaiZhu and FuZi could enhance the therapeutic effect of traditional Chinese medicine decoction on ACLF (Sun et al., 2010). However, the key active ingredients of these herbs' protection, especially BaiZhu and FuZi, against ACLF and the underlying mechanism remain unclear.

Network pharmacology is a novel multi-target therapeutic molecule design technique based on systems biology theory, network analysis of biological systems, and identifying particular signal nodes (Khanal and Patil, 2021; Zeng et al., 2022). It focuses on multimodal regulation of signal transduction pathways to maximize therapeutic efficacy while avoiding collateral side responses (Hopkins, 2008). Notably, TCM and global ethnic medicine target different molecules in the human body to achieve curative effectiveness (Hao da and Xiao, 2014; Zhou et al., 2020; Jiao et al., 2021). As a result, network-based pharmacology techniques in TCM research may be viable options for investigating the mechanism of WYJDHY treating ACLF. We searched TCMSP to acquire the major active ingredients of herbs in WYJDHY, identified drug and disease targets, used GEO expression profiles to analyze differentially expressed genes (DEGs) between ACLF and healthy samples, and identified overlapping genes as hub genes. The herb-active ingredient–signaling pathway–target networks were constructed. Atractylenolide I (AT-1) and its targeted pathway NF- κ B were chosen for cellular experiments. The effects of AT-1 on LPS-stimulated rat hepatocytes were investigated, and the involvement of NF- κ B signaling was evaluated.

Materials and methods

Retrieval of compound information in WYJDHY

The Traditional Chinese Medicine System Pharmacology Database (TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>) was used

TABLE 1 Main active ingredients with targeted genes in herbs of the Wenyang Jiedu Huayu formula, according to the TCMSP database and PubChem database.

TCM	Mol ID	Molecule name	MW	OB(%)	DL
BaiZhu	MOL000038	Acridine	179.23	33.71	0.1
	MOL000043	Atractylenolide I	230.33	37.37	0.15
	MOL000057	Diisobutyl phthalate	278.38	49.63	0.13
Chishao	MOL002714	Baicalein	270.25	33.52	0.21
	MOL002776	Baicalin	446.39	40.12	0.75
	MOL000358	Beta-sitosterol	414.79	36.91	0.75
	MOL000492	Cianidanol	290.29	54.83	0.24
	MOL000449	Stigmasterol	412.77	43.83	0.76
Danshen	MOL002776	Baicalin	446.39	40.12	0.75
	MOL007088	Cryptotanshinone	296.39	52.34	0.4
	MOL000569	Digallic acid	322.24	61.85	0.26
	MOL001942	Isoimperatorin	270.3	45.46	0.23
	MOL000006	Luteolin	286.25	36.16	0.25
	MOL007122	Miltirone	282.41	38.76	0.25
	MOL007154	Tanshinone IIA	294.37	49.89	0.4
YiYiRen	MOL000953	Cholesterol	386.73	37.87	0.68
	MOL001884	Demecolcine	371.47	26.6	0.51
	MOL000508	Friedelin	426.8	29.16	0.76
	MOL000449	Stigmasterol	412.77	43.83	0.76
Yinchen	MOL000358	Beta-sitosterol	414.79	36.91	0.75
	MOL007274	Cirsimaritin	314.31	30.35	0.3
	MOL005573	Genkwanin	284.28	37.13	0.24
	MOL000354	Isorhamnetin	316.28	49.6	0.31
	MOL000098	Quercetin	302.25	46.43	0.28
FuZi	MOL002398	Karanjin	292.3	69.56	0.34
	MOL000131	Linoleic acid	280.5	41.9	0.14

to collect the chemical ingredients of BaiZhu, Chishao, DanShan, YiYiRen, YinChen, and FuZi (Table 1) (Ru et al., 2014). The active compounds were screened based on absorption, distribution, metabolism, and excretion (ADME), and bio-active components were recovered for further study using pharmacokinetic information retrieval filters under screening conditions of OB 20% (Xu et al., 2012) and DL \geq 0.1 (Jia et al., 2020).

Retrieval of compound targets and disease targets

PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) and PubMed (<https://pubmed.ncbi.nlm.nih.gov/>) were used to find the protein targets of the active chemicals in BaiZhu, Chishao, DanShan, YiYiRen, YinChen, and FuZi.

Searching for 'ACLF' on GeneCards and comparing differentially expressed genes (DEGs) between ACLF and normal samples yielded the disease target genes of ACLF.

DEGs between ACLF and normal samples

GSE142255 was downloaded and analyzed for DEGs between seven cases of normal control and nine cases of ACLF samples combined by the metaMA package. The threshold was set as $|\log_{2}FC| > 1$ and FDR < 0.05 .

Gene Ontology functional and KEGG signaling pathway enrichment annotation for 105 hub genes

The GO and KEGG signaling enrichment analyses were conducted using the functional annotation tool of Metascape (<https://metascape.org/gp/>) (Zhou Y. et al., 2019). Terms with thresholds of Count ≥ 2 and Expression Analysis Systematic Explorer (EASE) scores ≤ 0.05 were chosen in functional annotation clustering.

Protein–protein interaction analysis

PPI data were retrieved from STRING (<https://string-db.org/cgi/input.pl>), and a physical score > 0.132 was applied to construct a PPI network. Only interactions with weight greater than the threshold were chosen for the newly built PPI network.

Construction and analysis of networks

The ingredient–target–pathway networks were constructed by Cytoscape_v3.8.0 (Smoot et al., 2011). In these graphical networks, the herbs, compounds, pathways, or targets were represented by nodes, while the compound–target or target–pathway interactions were represented by edges.

Cell lineage and LPS stimulation

The rat hepatocyte cell line BRL 3A was procured from Procell (CL-0038, China) and cultivated in Dulbecco's modified Eagle's medium (DMEM, Gibco, Carlsbad, CA, United States) added with 10% FBS (Gibco). For the cellular inflammation model induction, BRL 3A cells were treated with 1 $\mu\text{g}/\text{ml}$ LPS for 24 h.

The maximum non-cytotoxic concentration of atractylenolide I (AT-1)

BRL 3A cells were treated for 24 and 48 h with gradient doses of AT-1 (0, 1, 5, 10, 20, 40, and 80 μM , obtained from Xiya

TABLE 2 Primer sequence for the study.

Gene	Primer	Sequence (5'-3')
ALT	Forward	TGCGGGTTTCGTGGTGGCTAT
	Reverse	TCGGAGGGTGTGGCGGACT
AST	Forward	CGGGACTTGGTCTCACATCACT
	Reverse	GGAGGTAGCCACGTAATCTAGGTTC
IL-6	Forward	TTCACAGAGGATACCACCCACAA
	Reverse	ACCAGAGCAGATTTCAATAGGCA
VCAM-1	Forward	CGGCATTTATGTATGTGAAGGGAT
	Reverse	TCTTTGACGCTCTTAGATGGGAAG
ICAM-1	Forward	TCTGTCAAACGGGAGATGAATGG
	Reverse	TCTGGCGGTAATAGGTGTAATGG
CRP	Forward	CATCTGTGCCACCTGGGAGTCT
	Reverse	AAAGCCACCGCCATACGAGTC
IL-10	Forward	TGGACAACATACTGCTGACAGATTC
	Reverse	TCCACTGCCTTGCTTTTATTTCTC
GAPDH	Forward	GCCTTCCGTGTTCTACCCC
	Reverse	CGCCTGCTTACCACCTTCT
β -actin	Forward	CCGTAAAGACCTCTATGCCAACA
	Reverse	GAGCCACCAATCCACACAGAGT

Reagent, China). CCK-8 assays were subsequently conducted to examine cell viability, and the maximum non-cytotoxic concentration of AT-1 was selected.

Cell counting kit-8

BRL 3A cells were seeded onto 96-well plates and cultured with AT-1 for 24 h (with or without LPS) for cell viability determination. The vitality of the cells was then determined using CCK-8, as directed by the manufacturer. In each well, 10 μ l of cell counting kit solution was supplemented, followed by the incubation of 96-well plates at 37°C for 2 h. A microplate reader at 490 nm was then used to measure the absorbencies.

Flow cytometry

An annexin-V-fluorescein isothiocyanate (FITC) kit (BD Biosciences, San Jose, CA, United States) was used to measure the proportion of cells undergoing apoptosis. BRL 3A cells were treated with AT-1, collected, resuspended in 500 μ l augmented binding buffer, and incubated for 15 min at 25°C in the dark in a reagent mix comprising 5 μ l of the annexin-V-FITC conjugate and 10 μ l of PI. The samples were analyzed using a flow cytometer (Novocyte, Agilent, United States) to determine the cell percentage at various phases.

For detecting lymphocyte subsets, 100 μ l of the blood sample was stained with 10 μ l of FITC-conjugated CD3, PE-conjugated

CD4, and APC-conjugated CD8 reagent (Beckman Coulter), followed by incubation for 15 min in the dark for lysis of red blood cells. After washing, the cells were resuspended and subjected to flow cytometric analysis (Beckman). Lymphocytes were defined with their forward and side scatter characteristics. T lymphocytes were identified (CD3⁺) and then subdivided into CD4⁺ or CD8⁺ populations.

Biochemistry analysis and ELISA

The ALT and AST levels in the culture medium supernatant or rats' serum were determined using the ALT and AST assay kits (Nanjing Jiancheng Bioengineering Institute, China). The IL-6 and VCAM levels in the culture medium supernatant or rats' serum were evaluated using rat IL-6 and VCAM-1 ELISA kits (Lunchangshuo Bio, China), respectively. Serum TPRO, ALB, TBIL, PCT, IL-10, ICAM-1, and CRP levels were examined using corresponding rat ELISA kits (Lunchangshuo Bio).

qRT-PCR

The TRIzol reagent (Invitrogen, Carlsbad, United States) was used to isolate total RNA from cells and liver tissues. cDNA was synthesized using total RNA (2 μ g), and Green Supermix (Roche, Basel, Switzerland) was used to conduct the real-time polymerase chain reaction (RT-PCR) on an ABI7900HT fast real-time PCR system (Applied Biosystems, CA, United States). GAPDH and β -actin was used as an internal control. The primer sequences used in qRT-PCR are listed in Table 2.

Immunoblotting

The target cells were used to isolate the proteins. The isolated proteins were deposited onto the PVDF membrane after electrophoresis with SDS-PAGE and then determined by immunoblotting with the specified primary antibodies. TLR4 (1/1000, ab13556, Abcam), NF- κ B p65 (1/1000, 8242S, Cell Signaling Technology, Danvers, United States), p-NF- κ B p65 (1/500, ab194726, Abcam), and actin (use concentration of 1 μ g/ml, ab8226, Abcam, endogenous control) antibodies were used in this study. Antirabbit or antimouse IgG antibodies conjugated to horseradish peroxidase (Abcam) were used to cultivate the membranes. The protein bands were seen using the Thermo Scientific Pierce ECL Western Blotting Substrate.

Animals and experiment design

Male SD rats (weighing 130–150 g, $n = 24$) were purchased from SLAC laboratory animal company (Changsha, China). All

rats were kept under specific-pathogen-free (SPF) conditions with free access to food and drinking water at a room temperature of 22°C–25°C and humidity of (50.0 ± 2.0) %. The lights were turned on every 12 h for illumination. All procedures were approved by the animal ethics committee of Hunan University of Chinese Medicine (ZYFY20211111).


The rats were randomly allocated into four groups: control ($n = 6$), ACLF model ($n = 6$), ACLF model + AT-1 ($n = 6$), and ACLF model + AT-1 + PDTTC ($n = 6$). The rats, except for the control group, were subcutaneously injected 0.5 ml of bovine serum mixed Freund's incomplete adjuvant (contained 8 mg/ml bovine serum) on days 0, 14, 24, and 34. Then, the rats received tail vein injections 12 times (twice a week for 6 weeks) with bovine serum saline solution (5 mg/ml for 1st injection, 6.25 mg/ml for 2nd injection, 7.5 mg/ml for 3rd injection, 8.75 mg/ml for 4th injection, 10 mg/ml for 5th–12th injection, 400 μ l) to generate an immune liver fibrosis model. For inducing the ACLF model, rats with immune liver fibrosis were fasted for 12 h and then intraperitoneally injected with LPS at a dose of 100 μ g/kg and D-galactosamine (D-GalN) (Sigma-Aldrich, United States, G0500) at a dose of 400 mg/kg (Li et al., 2017). For PDTTC treatment, PDTTC (15 mg/kg) was intraperitoneally injected

30 minutes before the ACLF induction. For AT-1 treatment, AT-1 (20 mg/kg) was intraperitoneally injected 30 minutes before the ACLF induction.

Then, 12 h after D-GalN and LPS challenge, the rats were sacrificed under anesthesia. The blood samples were collected from the abdominal aorta, and the liver was also collected. The right leaf was fixed in 10% neutral buffered formalin, and the rest of the liver was cut into small pieces and frozen in liquid nitrogen for further study.

Histological analysis

The liver specimens were embedded in paraffin and sectioned into 4- μ m thick tissue slices. All sections were first stained with hematoxylin and eosin (H&E) for morphological structure analysis. For immunohistochemical staining (IHC), after antigen retrieval and endogenous peroxidase blocking, the sections were incubated with primary antibodies against TLR4 (1/100, 19811-1-AP, Proteintech, Wuhan, China), p-NF- κ B p65 (1/50, ab194726, Abcam), IL-6 (use concentration of 1 μ g/ml, ab9324, Abcam), and VCAM-1 (1/500, ab134047, Abcam) at 4 °C overnight and then incubated with secondary antibodies at room temperature for 2 h. Freshly



prepared 3,3'-diaminobenzidine solution (Boster) was used for coloration. Next, the sections were counterstained with hematoxylin. The brown color indicated positive staining.

Statistical analysis

The cell experiments were performed at least three times, and the animal experiments were performed at least six times. Experimental data from individual experiments were presented as the mean \pm standard deviation (SD). Using GraphPad Prism software, comparisons between conditions were conducted by Student's t-test or one-way ANOVA with Tukey's test *post hoc* analysis. $p < 0.05$ was deemed as a statistically significant difference.

Results

Drug targets of the Wenyang Jiedu Huayu formula and disease targets of ACLF

First, the active compounds of six main herbs of WYJDHY, namely, BaiZhu, Chishao, DanShan, YiYiRen, YinChen, and FuZi, were retrieved from TCMSP setting the threshold as OB \geq 20% and DL \geq 0.1. Those compounds were applied for PubChem analysis, and 23 compounds with targeted genes were obtained (Table 1). A total of 6,386 drug target genes were obtained based on 23 compounds. Regarding disease targets, 8,096 genes were associated with ACLF, according to the GeneCards database, among which 3,132 were drug targets obtained from the last step. Next, differentially expressed genes (DEGs) between normal and ACLF samples were analyzed according to GSE142255 (Figure 1A); using the thresholds of $|\log_{2}FC| > 1$ and $\text{adj.P.Val} < 0.05$, a total of 105 DEGs were identified as the co-targets of drug and disease (Figure 1B–C, due to limited space, Figure 1C only showed the part of genes' name; 105 DEGs are listed in Supplementary Table S1).

Gene Ontology functional and KEGG signaling pathway enrichment annotation on 105 hub genes

Functional and signaling pathway enrichment annotation was conducted upon these 105 DEGs using Metascape. As inferred from Figure 2, 105 DEGs were significantly associated with biological activities such as lymphocyte activation, reactive oxygen species metabolism, MAPK cascade regulation, and immune response regulation (Figures 2A,B) and pathways such as Th17 cell differentiation, cancer transcriptional dysregulation, phagosome, IBD, and NF- κ B signaling (Figures 2C,D). Our previous study has confirmed that WYJDHY could modulate TLR4/NF- κ B signaling during hepatic failure (Chen


et al., 2013). Therefore, in the following investigation, we mainly focus on the active compounds that target NF- κ B signaling.

The herb–compound–signaling and herb–signaling–target networks

Protein–protein interaction (PPI) analysis was performed on 105 hub genes using STRING (<https://string-db.org/cgi/input.pl>) with a physical score > 0.132 ; Figures 3A,B show that 105 DEGs could be clustered into four functional modules. Cytoscape_v3.8.0 was used to construct the herb–compound–signaling–target networks (Smoot et al., 2011). The herbs, compounds, proteins, or pathways were represented by nodes in these graphical networks, whereas the interactions between the herb, compound, target, or signaling were represented by edges (Figure 3C–D, Supplementary Table S2, S3). A total of 16 active compounds could target 52 pathways. As inferred from Figures 3C,D and Supplementary Table S2, S3, the compounds AT-1 and diisobutyl phthalate, respectively, from warming Yang function herbs BaiZhu and FuZi, have been regarded as the hub compounds for targeting the NF- κ B pathway. Among them, AT-1 has been reported to ameliorate acute liver injury in mice (Du et al., 2022). Therefore, we chose AT-1 for further investigation.

Effects of AT-1 on LPS-induced toxicity in rat hepatocytes


For investigating the functions of AT-1, an LPS-induced toxicity model was placed in rat hepatocytes, the BRL 3A cell line. The target cells were treated for 24 and 48 h with gradient doses of AT-1 (0, 1, 5, 10, 20, 40, or 80 μ M) and examined for cell viability to determine the minimum efficient concentration; as inferred from Figure 4A, 10 μ M AT-1 did not affect the cell viability that was used in the following experiments. Then, BRL 3A cells were treated with LPS with or without 10 μ M AT-1 and examined for 1 μ g/ml LPS-stimulated toxicity. Figures 4B–D show that LPS stimulation inhibited cell viability and promoted cell apoptosis, which could be partially eliminated by AT-1 treatment. As for liver function markers and cytokines, LPS stimulation significantly increased the ALT, AST, IL-6, and VCAM-1 levels within the culture medium or cells, whereas AT-1 treatment partially reduced the contents of these factors (Figures 4E,F). Given the crucial role of NF- κ B signaling in ACLF (Yang et al., 2014; Zhang et al., 2015; Zhou et al., 2018), the alterations in related factors were also investigated. As shown in Figure 4G, TLR4 protein levels were increased, and p65 phosphorylation was significantly promoted by LPS stimulation, whereas AT-1 treatment partially attenuated LPS effects on NF- κ B signaling.



NF- κ B signaling is involved in AT-1 effects on LPS-induced toxicity in rat hepatocytes

Regarding the involvement of NF- κ B signaling, the dynamic effects of AT-1 and/or the NF- κ B signaling inhibitor PDTC on BRL 3A cells were investigated. The target cells were treated with AT-1 (10 μ M) and/or PDTC (10 μ M) under LPS stimulation and examined for LPS-induced toxicity. Under LPS stimulation, single AT-1 or PDTC treatment dramatically enhanced cell viability but suppressed cell apoptosis, and the alterations were further

amplified by combining AT-1 and PDTC (Figures 5A,B). Under LPS stimulation, single AT-1 or PDTC treatment remarkably decreased the ALT, AST, IL-6, and VCAM-1 levels within the culture medium or cells, whereas the combination of AT-1 and PDTC reduced the ALT, AST, IL-6, and VCAM-1 levels even more (Figures 5C,D). Regarding the alterations in NF- κ B signaling, single AT-1 or PDTC treatment decreased TLR4 proteins and inhibited p65 phosphorylation, whereas AT-1 and PDTC combination exerted more inhibitory effects on NF- κ B signaling (Figure 5E).



NF- κ B signaling is involved in AT-1 protection on the ACLF rat model

For validating the effects and mechanism of AT-1 on ACLF *in vivo*, a rat model was established as described, and treatments were administrated accordingly (Figure 6A). However, 12 h after the acute attacks, the ALT and AST levels in the serum or liver tissues were significantly elevated in ACLF model rats, whereas lowered by single AT-1 treatment or the combination of AT-1 and PDTTC treatments compared with the model rats; furthermore, the combination significantly decreased the ALT and AST levels compared with single AT-1 treatment (Figures 6B,C). Liver function evaluation was further evidenced by histopathological examinations. In ACLF model rats, H&E staining shows that

hepatic fibrosis was evident, pseudolobules were widely developed, hepatocytes were disordered, and necrosis was severe; the following symptoms were also observed: a large number of inflammatory cell infiltration, hepatic sinusoidal dilatation, and bleeding, with certain liver tissues displaying major or submassive necrosis (Figure 6D). These pathological changes were ameliorated by single AT-1 treatment or the combination of AT-1 and PDTTC treatments (Figure 6D).

Regarding local inflammation, the levels of TLR4 and p-p65 were dramatically increased in liver tissues of ACLF model rats, whereas partially decreased by single AT-1 treatment or the combination of AT-1 and PDTTC treatments; moreover, the combination significantly decreased the TLR4 and p-p65 levels compared with single AT-1 treatment (Figures 6F,G).




FIGURE 4

Effects of atractylenolide I (AT-1) on LPS-induced toxicity in rat hepatocytes. (A) BRL 3A cells were treated with gradient doses of AT-1 (0, 1, 5, 10, 20, 40, and 80 μ M) for different time points and examined for cell viability using CCK-8 assays. Then, BRL 3A cells were treated with LPS in the presence or absence of 10 μ M AT-1 and examined for cell viability using the CCK-8 assay (B), cell apoptosis by flow cytometry (C–D), the levels of ALT, AST, IL-6, and VCAM-1 in culture medium or cells using corresponding kits or qRT-PCR assay, respectively (E–F), and the protein levels of TLR4, p-NF- κ B/p65, and NF- κ B/p65 by immunoblotting (G). N = 3; * p < 0.05, ** p < 0.01 compared to the control group; ## p < 0.01 compared to the LPS group.

Furthermore, the serum of rats was collected for ELISA. ALB and TPRO were decreased, but TBIL and PCT were increased in ACLF rats, whereas opposite trends of these indexes were

observed in single AT-1 treatment or the combination of AT-1 and PDTc groups (Figures 7A–D). Similarly, the combination of AT-1 and PDTc further amplified the improving effects of




FIGURE 5

NF- κ B signaling is involved in AT-1 effects on LPS-induced toxicity in BRL 3A cells. Target cells were treated with AT-1 (10 μ M) and/or PDTC (the NF- κ B signaling inhibitor, 10 μ M) under LPS stimulation and examined for cell viability using CCK-8 assays (A), cell apoptosis by flow cytometry (B), levels of ALT, AST, IL-6, and VCAM-1 in the culture medium or cells using corresponding kits or qRT-PCR assay, respectively (C–D), and protein levels of TLR4, p-NF- κ B/p65, and NF- κ B/p65 by immunoblotting (E). N = 3; * p < 0.05, and ** p < 0.01 compared to the control group; # p < 0.05 and ## p < 0.01 compared to the AT-1 group.

single AT-1 treatment on these indexes (Figures 7A–D). Next, lymphocyte subgroups were examined. Total CD3⁺ T-cell counts were considerably lower in ACLF rats, with the increase in the CD8⁺ subset and decrease in the CD4⁺ subset; single AT-1 treatment or the combination of AT-1 and PDTC increased CD3⁺ T-cell counts, with the decrease in the CD8⁺ subset and increase in the CD4⁺ subset (Figure 7E). Last, the levels of IL-6, IL-10, VCAM-1, ICAM-1, and CRP in the serum or liver tissues

were examined, and the levels of IL-6 and VCAM-1 in liver tissues were detected. Consistent with local inflammatory changes, serum and tissue IL-6, IL-10, VCAM-1, ICAM-1, and CRP and tissue IL-6 and VCAM-1 levels were significantly increased in ACLF rats; single AT-1 treatment or the combination of AT-1 and PDTC remarkably decreased the levels of these inflammatory factors, and the combination of AT-1 and PDTC decreases these factors more (Figures 8A–F).





FIGURE 6

NF- κ B signaling is involved in AT-1 protection in the acute-on-chronic liver failure (ACLF) rat model. (A) Schematic diagram showing the procedures of the ACLF rat model and AT-1 or PDTC treatment. The rats were randomly allocated into control ($n = 6$), ACLF model ($n = 6$), ACLF model + AT-1 ($n = 6$), and ACLF model + AT-1 + PDTC ($n = 6$) groups and treated accordingly. (B–C) Levels of ALT and AST were determined using ELISA in the serum or qRT-PCR assay in liver tissues. (D) Histopathological changes in liver tissues were evaluated by H&E staining. (E–F) Levels of TLR4 and p-p65 in liver tissues were evaluated by immunohistochemical staining (IHC). (G) Levels of TLR4, p-p65, and p65 in liver tissues were evaluated by immunoblotting. $N = 6$; ** $p < 0.01$ compared to the control group; ## $p < 0.01$ compared to the ACLF model group; & $p < 0.05$ and && $p < 0.01$ compared to ACLF+AT-1 group.

Discussion


In this study, 23 compounds with 6,386 drug targets were obtained, and 8,096 genes were identified as ACLF disease targets, according to the GeneCards database, among which 3,132 were overlapping co-targets. Expression profile analysis identified 105 DEGs among the co-targets. These 105 DEGs were significantly associated with biological activities such as lymphocyte

activation, reactive oxygen species metabolism, MAPK cascade regulation, immune response regulation, and pathways such as Th17 cell differentiation, cancer transcriptional dysregulation, phagosome, IBD, and NF- κ B signaling. After PPI analysis and network construction, AT-1 from the warming Yang herb BaiZhu has been identified as the hub active ingredient of the WYJDHY formula that could target and regulate NF- κ B signaling. In cellular experiments, LPS stimulation inhibited rat hepatocyte viability,



promoted cell apoptosis, increased the ALT, AST, IL-6, and VCAM-1 levels within the culture medium, and activated NF- κ B signaling, whereas AT-1 treatment significantly attenuated LPS-induced toxicity on BRL 3A cells. Furthermore, the NF- κ B signaling inhibitor PDTC exerted similar effects on LPS-stimulated BRL 3A cells to those of AT-1, and the combination of PDTC and AT-1 further attenuated LPS-induced toxicity on BRL 3A cells. *In vivo*, single AT-1 or the combination of PDTC and AT-1 significantly improved liver dysfunctions and local inflammation in ACLF model rats; the combination of PDTC and AT-1 improved the symptoms more.

The protective functions of the six main herbs of WYJDHY on liver disorders have been reported previously. *Paeonia lactiflora* Pall. (PLP), also named Chishao, exerted an anti-inflammatory effect on the alpha-naphthylisothiocyanate (ANIT)-induced cholestasis model (Ma et al., 2018). FuZi, the monarch drug of another TCM formula Fuzi Lihong decoction, exerted protective effects against non-alcoholic fatty liver disease (NAFLD) through anti-inflammatory responses (Yang et al., 2018; Yang et al., 2020). Single Yinchen or the combination of Yinchen with other herbs could protect against hepatocyte apoptosis (Zhang et al., 2022a), non-



alcoholic fatty liver disease (Guo et al., 2017), or ANIT-induced cholestatic liver injury (Su et al., 2021). Compounds such as salvianolic acid C (Wu et al., 2019) and salvianolic acid A protect against drug-induced acute liver failure or CCl_4 -induced liver fibrosis. Pan et al. (2021) demonstrated the liver-protective effects of Shenling Baizhu San against inflammatory damage through TLR4/NLRP3 signaling in rats with NAFLD. In this study, 23 main compounds from six herbs were obtained; these herbs might target 3,132 of the 8,096 ACLF disease targets *via* expression profile analysis. Of the 3,132 co-targets, 105 have been found to be differentially expressed between ACLF and normal samples.

For identifying the main functions and signaling pathways that these compounds might affect, these 105 DEGs were applied for GO

functional and KEGG signaling pathway enrichment annotation. GO annotation showed that they were significantly associated with biological activities such as lymphocyte activation, reactive oxygen species metabolism, MAPK cascade regulation, and immune response regulation, whereas KEGG pathway annotation showed that they were remarkably enriched in Th17 cell differentiation, cancer transcriptional dysregulation, phagosome, IBD, and NF- κ B signaling. As aforementioned, the NF- κ B pathway, a vital component of TLRs, exerts a crucial effect on regulating ACLF severity and prognosis (Hayden and Ghosh, 2008; Sun et al., 2009; McCabe et al., 2012; Yang et al., 2014; Zhang et al., 2022b). Our previous study has confirmed that WYJDHY could modulate TLR4/NF- κ B signaling during hepatic failure [23]. Several reagents have

been reported to alleviate ACLF through regulating the NF- κ B pathway, including trichostatin A (Zhang et al., 2015), ginsenoside Rg1 (Zhao et al., 2021), and plumbagin (Wang H. et al., 2016). Considering that the six main herbs exert their protective effects against liver disorders through regulating inflammatory signaling or factors, GO and KEGG annotation results were consistent with the etiology of ACLF, suggesting that the 23 major active compounds might exert their functions *via* inflammatory signaling, particularly the NF- κ B pathway. After PPI analysis and network construction, AT-1 from the warming Yang herb BaiZhu had been identified as the hub active ingredient of the WYJDHY formula for targeting the NF- κ B pathway and was chosen for following cellular experiments.

Reportedly, in an acetaminophen-induced acute liver failure mouse model, both LPS-TLR4 pathway therapies reduced cell death, increased renal function, and decreased the coma-free survival rate (Shah et al., 2013), suggesting that the LPS-TLR4 axis is implicated in inflammatory processes that lead to tissue damage, and blocking this signaling pathway stops disease development. Therefore, in this study, an LPS-induced toxicity model was established in rat hepatocyte BRL 3A cells, and the effects of AT-1 were investigated. Consistent with previous studies, LPS stimulation inhibited cell viability, enhanced cell apoptosis, and promoted the levels of ALT, AST (liver function markers), IL-6, and VCAM-1 (cytokines) (Shah et al., 2013; Chen et al., 2018; Wu et al., 2021; Zhang et al., 2021). As expected, AT-1 treatment significantly ameliorated LPS-induced toxicity on BRL cells by rescuing cell viability, suppressing cell apoptosis, and decreasing ALT, AST, IL-6, and VCAM-1 levels. Considering the critical roles of the NF- κ B pathway, a vital part of TLRs, in ACLF (Hayden and Ghosh, 2008; Yang et al., 2014; Zhang et al., 2022b), the effects of AT-1 on the NF- κ B pathway were investigated in LPS-stimulated BRL 3A cells. Consistently, LPS-induced activation could be significantly inhibited by AT-1 treatment. Moreover, the combination of PDTC, the NF- κ B pathway inhibitor, and AT-1 further attenuated LPS-induced toxicity on BRL 3A cells and NF- κ B pathway activation, suggesting that AT-1 might exert the hepatic protective effects through inhibiting the NF- κ B pathway.

The most common cause of ACLF is liver fibrosis/cirrhosis. Continuous inflammation, SIRS, and cytokine storms result from acute damage caused by alcohol use, hepatotropic viral infection, or medications; they play a key role in the pathophysiology of liver failure and subsequent organ failure (Sarin and Choudhury, 2016). Rat serum levels of ALT, AST, TBIL, and PCT increased dramatically after injection with LPS/D-GalN, and a considerable number of infiltrating inflammatory cells and necrotic hepatocytes were identified in liver tissues (Li et al., 2017; Sarin et al., 2019). These findings matched the clinical and pathological abnormalities seen in ACLF, showing that the ACLF rat model was built successfully. The liver functions improved after treatment with AT-1 alone or in conjunction with PDTC, as manifested by decreased ALT, AST, TBIL, and PCT levels and increased histopathological features of liver tissues. Furthermore, AT-1 alone or in conjunction with PDTC raised

CD3⁺ T-cell numbers while decreasing CD8⁺ subsets and increasing CD4⁺ subsets. In the progression of ACLF, the TLR4 signaling pathway is stimulated, and the production of NF- κ B is increased in the context of local inflammation. The NF- κ B pathway has long been considered a prototypical pro-inflammatory signaling pathway, largely based on the role of NF- κ B in the expression of pro-inflammatory genes, including cytokines, chemokines, and adhesion molecules (Lawrence, 2009). Pro-inflammatory factors such as IL-1, IL-18, IL-6, and TNF- α are released *via* the NF- κ B-mediated inflammatory cascade (Moreau, 2016). Zhang et al. (2022b) elucidated that cylindromatosis regulates IL-6 by inhibiting NF- κ B. Zhang et al. (2019) revealed that methane ameliorates cognitive dysfunction by promoting IL-10 expression and inhibiting the NF- κ B pathway in aging mice. In this investigation, single AT-1 or in conjunction with PDTC reduced the levels of these inflammatory factors considerably, and with the combination of AT-1 and PDTC, lowering them more. Therefore, AT-1 might help ameliorate symptoms and local inflammation in ACLF model rats, and NF- κ B signaling might play a role.

In conclusion, 23 active ingredients of six herbs in the WYJDHY formula were retrieved, and 105 co-targets of drugs and disease were identified to be differentially expressed between ACLF and normal tissues. AT-1 protects against LPS-induced toxicity on hepatocytes, and the NF- κ B pathway might be involved.

Data availability statement

Publicly available datasets were analyzed in this study. These data can be found at: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142255>.

Ethics statement

The animal study was reviewed and approved by the animal ethics committee of Hunan University of Chinese Medicine (ZYFY20211111).

Author contributions

Visualization: DT, R-YW, and LD; methodology: DT, R-YW, and YM; investigation: YW; writing—original draft: DT and R-YW; writing—review and amp; and editing: K-WS.

Funding

This study was supported by the National Natural Science Foundation of China (8197152432 and 82104809) and the Hunan University of Chinese Medicine Graduate student innovation topics (2020CX18).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2022.1003479/full#supplementary-material>

References

- Arroyo, V., Moreau, R., Jalan, R., Gines, P., and Study, E.-C. C. C. (2015). Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. *J. Hepatol.* 62, S131–S143. doi:10.1016/j.jhep.2014.11.045
- Bernal, W., Jalan, R., Quaglia, A., Simpson, K., Wendon, J., and Burroughs, A. (2015). Acute-on-chronic liver failure. *Lancet* 386, 1576–1587. doi:10.1016/S0140-6736(15)00309-8
- Chen, B., Wang, J., Peng, J., Li, W., Su, X., Zhu, W., et al. (2013). Effect of wenyang jie-du hua-yu granules on TLR4 and NF- κ B expression of rat hepatic failure model with intestinal endotoxemia. *World Sci. Technology-Modernization Traditional Chin. Med.* 15, 818–824. doi:10.11842/wst.2013.05.004
- Chen, X., Yan, X., and Guo, L. (2018). Inhibitory effect of Patrinoa on BRL-3A cell apoptosis through the TLR4/PI3K/AKT/GSK3 β and TLR4/P38/JNK signaling pathways. *Mol. Med. Rep.* 17, 5344–5349. doi:10.3892/mmr.2018.8466
- Chen, Z., Wang, X., Li, Y., Wang, Y., Tang, K., Wu, D., et al. (2019). Comparative network pharmacology analysis of classical TCM prescriptions for chronic liver disease. *Front. Pharmacol.* 10, 1353. doi:10.3389/fphar.2019.01353
- Du, Z., Ma, Z., Lai, S., Ding, Q., Hu, Z., Yang, W., et al. (2022). Atractylenolide I ameliorates acetaminophen-induced acute liver injury via the TLR4/MAPKs/NF- κ B signaling pathways. *Front. Pharmacol.* 13, 797499. doi:10.3389/fphar.2022.797499
- Gao, F., Sun, L., Ye, X., Liu, Y., Liu, H., Geng, M., et al. (2017). Development and validation of a prognostic model for acute-on-chronic Hepatitis B liver failure. *Eur. J. Gastroenterol. Hepatol.* 29, 669–678. doi:10.1097/MEG.0000000000000854
- Guo, Y., Li, J. X., Wang, Y. L., Mao, T. Y., Chen, C., Xie, T. H., et al. (2017). Yinchen linggui zhugan decoction ameliorates nonalcoholic fatty liver disease in rats by regulating the Nrf2/ARE signaling pathway. *Evid. Based. Complement. Altern. Med.* 2017, 6178358. doi:10.1155/2017/6178358
- Hao Da, C., and Xiao, P. G. (2014). Network pharmacology: A rosetta stone for traditional Chinese medicine. *Drug Dev. Res.* 75, 299–312. doi:10.1002/ddr.21214
- Hayden, M. S., and Ghosh, S. (2008). Shared principles in NF- κ B signaling. *Cell* 132, 344–362. doi:10.1016/j.cell.2008.01.020
- Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. *Nat. Chem. Biol.* 4, 682–690. doi:10.1038/nchembio.118
- Jia, C. Y., Li, J. Y., Hao, G. F., and Yang, G. F. (2020). A drug-likeness toolbox facilitates ADMET study in drug discovery. *Drug Discov. Today* 25, 248–258. doi:10.1016/j.drudis.2019.10.014
- Jiao, X., Jin, X., Ma, Y., Yang, Y., Li, J., Liang, L., et al. (2021). A comprehensive application: Molecular docking and network pharmacology for the prediction of bioactive constituents and elucidation of mechanisms of action in component-based Chinese medicine. *Comput. Biol. Chem.* 90, 107402. doi:10.1016/j.compbiolchem.2020.107402
- Kabbani, A. R., Tergast, T. L., Manns, M. P., and Maasoumy, B. (2021). Treatment strategies for acute-on-chronic liver failure. *Med. Klin. Intensivmed. Notfmed.* 116, 3–16. doi:10.1007/s00063-019-00613-x
- Kessoku, T., Kobayashi, T., Imajo, K., Tanaka, K., Yamamoto, A., Takahashi, K., et al. (2021). Endotoxins and non-alcoholic fatty liver disease. *Front. Endocrinol.* 12, 770986. doi:10.3389/fendo.2021.770986
- Khanal, P., and Patil, B. M. (2021). Integration of network and experimental pharmacology to decipher the antidiabetic action of *Duranta repens* L. *J. Integr. Med.* 19, 66–77. doi:10.1016/j.joim.2020.10.003
- Lad, N., Murphy, A. M., Parenti, C., Nelson, C. P., Williams, N. C., Sharpe, G. R., et al. (2021). Asthma and obesity: Endotoxin another insult to add to injury? *Clin. Sci.* 135, 2729–2748. doi:10.1042/CS20210790
- Lawrence, T. (2009). The nuclear factor NF- κ B pathway in inflammation. *Cold Spring Harb. Perspect. Biol.* 1, a001651. doi:10.1101/cshperspect.a001651
- Li, F., Miao, L., Sun, H., Zhang, Y., Bao, X., and Zhang, D. (2017). Establishment of a new acute-on-chronic liver failure model. *Acta Pharm. Sin.* B 7, 326–333. doi:10.1016/j.apsb.2016.09.003
- Liu, Q. (2009). Role of cytokines in the pathophysiology of acute-on-chronic liver failure. *Blood Purif.* 28, 331–341. doi:10.1159/000232940
- Liver, F. A. L. G. C. S. O. I. D. C. M. A., and Severe, L. D. A. L. G. C. S. O. H. C. M. A. (2013). Diagnostic and treatment guidelines for liver failure (2012 version). *J. Clin. Hepatol.* 16, 210–216. doi:10.3969/j.issn.1672-5069.2013.03.007
- Liver, F. A. L. G. C. S. O. I. D. C. M. A., and Severe, L. D. A. L. G. C. S. O. H. C. M. A. (2019). Guideline for diagnosis and treatment of liver failure. *Zhonghua Gan Zang Bing Za Zhi* 27, 18–26. doi:10.3760/cma.j.issn.1007-3418.2019.01.006
- Ma, X., Wen, J. X., Gao, S. J., He, X., Li, P. Y., Yang, Y. X., et al. (2018). *Paeonia lactiflora* Pall. regulates the NF- κ B-NLRP3 inflammasome pathway to alleviate cholestasis in rats. *J. Pharm. Pharmacol.* 70, 1675–1687. doi:10.1111/jph.13008
- Mccabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* 492, 108–112. doi:10.1038/nature11606
- Moreau, R. (2016). The pathogenesis of ACLF: The inflammatory response and immune function. *Semin. Liver Dis.* 36, 133–140. doi:10.1055/s-0036-1583199
- Napetschnig, J., and Wu, H. (2013). Molecular basis of NF- κ B signaling. *Annu. Rev. Biophys.* 42, 443–468. doi:10.1146/annurev-biophys-083012-130338
- Pan, M. X., Zheng, C. Y., Deng, Y. J., Tang, K. R., Nie, H., Xie, J. Q., et al. (2021). Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease. *J. Integr. Med.* 19, 428–438. doi:10.1016/j.joim.2021.07.004
- Ru, J., Li, P., Wang, J., Zhou, W., Li, B., Huang, C., et al. (2014). Tcmsp: A database of systems pharmacology for drug discovery from herbal medicines. *J. Cheminform.* 6, 13. doi:10.1186/1758-2946-6-13
- Sarin, S. K., and Choudhury, A. (2016). Acute-on-chronic liver failure: Terminology, mechanisms and management. *Nat. Rev. Gastroenterol. Hepatol.* 13, 131–149. doi:10.1038/nrgastro.2015.219
- Sarin, S. K., Choudhury, A., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., et al. (2019). Acute-on-chronic liver failure: Consensus recommendations of the asian pacific association for the study of the liver (APASL): An update. *Hepatol. Int.* 13, 353–390. doi:10.1007/s12072-019-09946-3
- Shah, N., Montes De Oca, M., Jover-Cobos, M., Tanamoto, K., Muroi, M., Sugiyama, K., et al. (2013). Role of toll-like receptor 4 in mediating multiorgan dysfunction in mice with acetaminophen induced acute liver failure. *Liver Transpl.* 19, 751–761. doi:10.1002/lt.23655
- Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L., and Ideker, T. (2011). Cytoscape 3.8: New features for data integration and network visualization. *Bioinformatics* 27, 431–432. doi:10.1093/bioinformatics/btq675
- Su, H., Wang, Q., Li, Y., Jin, J., Tan, B., Yan, D., et al. (2021). Effect of different ratios of yinchen and gancao decoction on ANIT-treated cholestatic liver injury in mice and its potential underlying mechanism. *Front. Pharmacol.* 12, 611610. doi:10.3389/fphar.2021.611610
- Sun, F., Chan, E., Wu, Z., Yang, X., Marquez, V. E., and Yu, Q. (2009). Combinatorial pharmacologic approaches target EZH2-mediated gene

- repression in breast cancer cells. *Mol. Cancer Ther.* 8, 3191–3202. doi:10.1158/1535-7163.MCT-09-0479
- Sun, K., Gong, L., and Chen, B. (2010). Chinese journal of integrated traditional and western medicine on liver diseases. *Efficacy Saf. Ganluxiaodudan (TCM decoction) Treat. patients chronic severe Hepat. B.* 20, 135–137.
- Wang, H., Zhang, H., Zhang, Y., Wang, D., Cheng, X., Yang, F., et al. (2016a). Plumbagin protects liver against fulminant hepatic failure and chronic liver fibrosis via inhibiting inflammation and collagen production. *Oncotarget* 7, 82864–82875. doi:10.18632/oncotarget.12655
- Wang, X., Chen, B., Peng, J., Sun, X., Sun, K., Li, W., et al. (2013). Effects of Wenyang Jiedu Huayu Granules on intestinal IgA in rats with liver failure and endotoxemia. *J. Liver Dis. Integr. Traditional Chin. West. Med.* 23, 157–159. doi:10.3969/j.issn.1005-0264.2013.03.009
- Wang, Z. L., Gao, S., Li, L., Li, X. Y., Huan, S. L., and Wang, K. (2016b). Demethylation of tumor necrosis factor- α converting enzyme predicts poor prognosis in acute-on-chronic Hepatitis B liver failure. *Clin. Res. Hepatol. Gastroenterol.* 40, 457–464. doi:10.1016/j.clinre.2015.12.004
- Wu, C. T., Deng, J. S., Huang, W. C., Shieh, P. C., Chung, M. I., and Huang, G. J. (2019). Salvianolic acid C against acetaminophen-induced acute liver injury by attenuating inflammation, oxidative stress, and apoptosis through inhibition of the keap1/nrf2/HO-1 signaling. *Oxid. Med. Cell. Longev.* 2019, 9056845. doi:10.1155/2019/9056845
- Wu, W., Sun, S., Wang, Y., Zhao, R., Ren, H., Li, Z., et al. (2021). Circulating neutrophil dysfunction in HBV-related acute-on-chronic liver failure. *Front. Immunol.* 12, 620365. doi:10.3389/fimmu.2021.620365
- Xu, X., Zhang, W., Huang, C., Li, Y., Yu, H., Wang, Y., et al. (2012). A novel chemometric method for the prediction of human oral bioavailability. *Int. J. Mol. Sci.* 13, 6964–6982. doi:10.3390/ijms13066964
- Yang, F., Li, X., Wang, L. K., Wang, L. W., Han, X. Q., Zhang, H., et al. (2014). Inhibitions of NF- κ B and TNF- α result in differential effects in rats with acute on chronic liver failure induced by d-Gal and LPS. *Inflammation* 37, 848–857. doi:10.1007/s10753-013-9805-x
- Yang, J., Ma, W., Mei, Q., Song, J., Shu, L., Zhang, S., et al. (2020). Protective effect of Fuzi Lizhong decoction against non-alcoholic fatty liver disease via anti-inflammatory response through regulating p53 and PPAR γ signaling. *Biol. Pharm. Bull.* 43, 1626–1633. doi:10.1248/bpb.b20-00053
- Yang, J. Y., Shi, Z. H., Ma, W., Tao, D. Q., Liu, S., Chen, L., et al. (2018). [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF- κ Bp65 pathway]. *Zhongguo Zhong Yao Za Zhi* 43, 3176–3183. doi:10.19540/j.cnki.cjcm.2018.0094
- Zeng, P., Su, H. F., Ye, C. Y., Qiu, S. W., Shi, A., Wang, J. Z., et al. (2022). A tau pathogenesis-based network pharmacology approach for exploring the protections of chuanxiong rhizoma in alzheimer's disease. *Front. Pharmacol.* 13, 877806. doi:10.3389/fphar.2022.877806
- Zhang, D., Li, N., Wang, Y., Lu, W., Zhang, Y., Chen, Y., et al. (2019). Methane ameliorates post-operative cognitive dysfunction by inhibiting microglia NF- κ B/ MAPKs pathway and promoting IL-10 expression in aged mice. *Int. Immunopharmacol.* 71, 52–60. doi:10.1016/j.intimp.2019.03.003
- Zhang, E., and Lu, M. (2015). Toll-like receptor (TLR)-mediated innate immune responses in the control of Hepatitis B virus (HBV) infection. *Med. Microbiol. Immunol.* 204, 11–20. doi:10.1007/s00430-014-0370-1
- Zhang, Q., Yang, F., Li, X., Wang, L. W., Chu, X. G., Zhang, H., et al. (2015). Trichostatin A protects against experimental acute-on-chronic liver failure in rats through regulating the acetylation of nuclear factor- κ B. *Inflammation* 38, 1364–1373. doi:10.1007/s10753-014-0108-7
- Zhang, X., Ge, J., Zhu, X., Zhang, H., Wang, Y., Xu, T., et al. (2022a). Effects and mechanism of oxymatrine combined with compound yinchen granules on the apoptosis of hepatocytes through the akt/FoxO3a/bim pathway. *Biomed. Res. Int.* 2022, 8644356. doi:10.1155/2022/8644356
- Zhang, X., Shang, X., Jin, S., Ma, Z., Wang, H., Ao, N., et al. (2021). Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats. *Arch. Biochem. Biophys.* 705, 108894. doi:10.1016/j.abb.2021.108894
- Zhang, X., Zhang, Y., Zhou, P., Ai, J., Liu, X., Zhang, Q., et al. (2022b). Down-regulated cylindromatosis enhances NF- κ B activation and aggravates inflammation in HBV-ACLF patients. *Emerg. Microbes Infect.* 11, 1586–1601. doi:10.1080/22221751.2022.2077128
- Zhao, J., He, B., Zhang, S., Huang, W., and Li, X. (2021). Ginsenoside Rg1 alleviates acute liver injury through the induction of autophagy and suppressing NF- κ B/NLRP3 inflammasome signaling pathway. *Int. J. Med. Sci.* 18, 1382–1389. doi:10.7150/ijms.50919
- Zhou, M., Li, S., and Pathak, J. L. (2019a). Pro-inflammatory cytokines and osteocytes. *Curr. Osteoporos. Rep.* 17, 97–104. doi:10.1007/s11914-019-00507-z
- Zhou, T., Sun, Y., Li, M., Ding, Y., Yin, R., Li, Z., et al. (2018). Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway. *Cell Death Dis.* 9, 590. doi:10.1038/s41419-018-0670-2
- Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., et al. (2019b). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* 10, 1523. doi:10.1038/s41467-019-09234-6
- Zhou, Z., Chen, B., Chen, S., Lin, M., Chen, Y., Jin, S., et al. (2020). Applications of network pharmacology in traditional Chinese medicine research. *Evid. Based. Complement. Altern. Med.* 2020, 1646905. doi:10.1155/2020/1646905
- Zou, Z., Li, B., Xu, D., Zhang, Z., Zhao, J. M., Zhou, G., et al. (2009). Imbalanced intrahepatic cytokine expression of interferon- γ , tumor necrosis factor- α , and interleukin-10 in patients with acute-on-chronic liver failure associated with Hepatitis B virus infection. *J. Clin. Gastroenterol.* 43, 182–190. doi:10.1097/MCG.0b013e3181624464
- Zuo, H. (2021). Efficacy of Wenyang Jiedu Huayu Formula in patients with liver failure and its effect on liver function and coagulation indexes. *J. Med Theor Prac* 34, 1677–1679.